RHD and trisomy 13: In recent years, NIPT has been gradually accepted as the screening test not only for its sensitivity (99%) and specificity (99.5%) for analysis of cffDNA to determine the risk of aneuploidies, including trisomy 13 (Patau Syndrome), trisomy 18 (Edwards Syndrome) and trisomy 21 (Down Syndrome), but also for determining fetus RhD status in RhD-negative mothers, fetus sex and single-gene disorders [50,51].